Charles A. Nicolette

Chief Executive Officer at CoImmune, Inc.

Charles A. Nicolette

Charles A. Nicolette

Chief Executive Officer at CoImmune, Inc.

Overview
Career Highlights

CoImmune, Inc.

RelSci Relationships

811

Number of Boards

1

Birthday

1963

Age

58
Relationships
View Relationship Details
RelSci Relationships are individuals Charles A. Nicolette likely has professional access to. A relationship does not necessarily indicate a personal connection.
Christopher A. Viehbacher

Co-Founder at Gurnet Point Capital LLC

Relationship likelihood: Strong

Alison Lawton

General Manager-Sanofi BioSurgery Business Unit at Genzyme Corp.

Relationship likelihood: Strong

Gail Sullivan

Treasurer at The Boston Consulting Group International, Inc.

Relationship likelihood: Strong

Louis J. Arcudi III

Chief Executive Officer & President at Millendo Therapeutics, Inc.

Relationship likelihood: Strong

Jeffrey D. Abbey

Chief Executive Officer & Director at Novadip Biosciences SA

Relationship likelihood: Strong

Frederick M. Miesowicz

Senior Vice President & General Manager (Hybridon Specialty Products) at Idera Pharmaceuticals, Inc.

Relationship likelihood: Strong

Gail J. Maderis

President, Chief Executive Officer & Director at Antiva Biosciences, Inc.

Relationship likelihood: Average

Timothy W. Trost

Chief Financial Officer at Werewolf Therapeutics, Inc.

Relationship likelihood: Average

Lori Harrelson

Former Vice President, Finance & Chief Accounting Officer at Argos Therapeutics, Inc.

Relationship likelihood: Average

Richard D. Katz

Chief Financial & Accounting Officer at Allena Pharmaceuticals, Inc.

Relationship likelihood: Average

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
In The News
GlobeNewswire
February 24, 2021
CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors
GlobeNewswire
December 16, 2020
Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH
Business Wire
November 19, 2020
Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020, a Novel Experimental Cell Therapy for Glioblastoma
GlobeNewswire
November 10, 2020
CoImmune, Inc. Announces Closing of $45 Million Series A Financing
Thomson Reuters ONE
April 30, 2020
CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.
Trending People
Chris A. Wray
Wray Defends FBI's Intelligence Sharing Ahead Of Jan. 6 Capitol Attack - npr.org
Carlos Ghosn Bichara
Your Wednesday Briefing - The New York Times
Lael Brainard
Lael Brainard hints that tumult in the bond market worried the Federal Reserve. - The New York Times
Rochelle Walensky
A Wave of Reopenings Takes Hold as Americans Ask Whether the Worst Is Over - The New York Times
Andrew Cuomo
Cuomo avoids public amid outcry over harassment allegations - Associated Press
Trending People
Chris A. Wray
Wray Defends FBI's Intelligence Sharing Ahead Of Jan. 6 Capitol Attack - npr.org
Carlos Ghosn Bichara
Your Wednesday Briefing - The New York Times
Lael Brainard
Lael Brainard hints that tumult in the bond market worried the Federal Reserve. - The New York Times
Rochelle Walensky
A Wave of Reopenings Takes Hold as Americans Ask Whether the Worst Is Over - The New York Times
Andrew Cuomo
Cuomo avoids public amid outcry over harassment allegations - Associated Press
Paths to Charles A. Nicolette
Potential Connections via
Relationship Science
You
Charles A. Nicolette
Chief Executive Officer at CoImmune, Inc.
Education
Ph.D Biochemistry, Cellular & Developmental Biology
State University of New York

The State University of New York is the largest comprehensive university system in the United States, educating approximately 468,000 students in more than 7,500 degree and certificate programs, and more than 1.8 million NYS citizens in professional development and personal enrichment programs, on 64 college and university campuses. There are nearly 3 million SUNY alumni worldwide.

Career History
Chief Executive Officer
Current
CoImmune, Inc.

CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC.

Director of Antigen Discovery
Tenure Unconfirmed
Genzyme Corp.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Chief Scientific Officer & Vice President, Research & Development
2003 - 2018
Argos Therapeutics, Inc.

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Transactions
Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Investments
Details Hidden
Argos Therapeutics, Inc.

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Other Affiliations

Charles A. Nicolette is affiliated with CoImmune, Inc., Genzyme Corp., Argos Therapeutics, Inc., Genzyme Molecular Oncology

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Charles A. Nicolette. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Charles A. Nicolette's profile does not indicate a business or promotional relationship of any kind between RelSci and Charles A. Nicolette.